EUCTR2008-001551-22-ES进行中（未招募）不适用
A randomized, double-blind, placebo controlled, multicenter, phase II study of adding AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) to first line chemotherapy in patients with optimally debulked ( < 1cm) epithelial ovarian cancer
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •- Histologically-confirmed optimally debulked (< 1 cm) FIGO stage III or stage IV (positive pleural cytology only) ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma.
- •- Patients should have undergone surgical debulking, by a surgeon experienced in the management of ovarian cancer, with the aim of maximal surgical cytoreduction. All patients must be optimally debulked as defined as having no residual tumor of greater than 1 cm in the post surgical setting.
- •- Patients with stage IV disease will be eligible if a positive pleural cytology is the only extra peritoneal disease.
- •- Paraffin block (or 10 – 20 unstained slides) and fresh frozen surgical/biopsy specimens of the primary tumor are required at baseline.
- •- No prior systemic treatment in the primary disease treatment setting.
- •- Female > 18 years of age or legal age.
- •- ECOG performance status = 2.
- •- Adequate organ and bone marrow function as evidenced by:
- •- hemoglobin = 9.0 g/dL,
- •- absolute neutrophil count = 1.5 x 109/L,
- •- platelet count = 100 x 109/L,
- •- Serum creatinine = 1.5 x ULN and measured or calculated creatinine clearance = 60 mL/min.
- •- AST and ALT = 2.5 x ULN
- •- total bilirubin = 1.5 x ULN unless increase is due to Gilbert’s disease or similar syndrome involving slow conjugation of bilirubin,
- •- Non diabetic patients or Type 1 or 2 Diabetic Patients:
- •- Diabetes must be controlled with HgbA1c < 8% and fasting blood glucose level <160 mg/dL.
- •- Patient must be willing and able to comply with scheduled visits, and all study procedures.
- •- Informed consent obtained.
- •- Patients should be able to commence systemic therapy within 6 weeks of cytoreductive surgery.
- •- Life expectancy > 12 weeks.
- •- Adequate coagulation parameters (within 14 days prior to randomization), International Normalized Ratio (INR) =1.5; Activated Prothrombin Time (APTT) = 1.5 x ULN.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Non-epithelial ovarian cancer, including malignant mixed Mullerian tumors.
- •- Borderline tumors (tumors of low malignant potential).
- •- Planned intraperitoneal cytotoxic chemotherapy.
- •- Prior systemic anticancer therapy for ovarian cancer.
- •- Any previous radiotherapy to the abdomen or pelvis.
- •- Patients with synchronous primary endometrial carcinoma, or a past history of primary endometrial carcinoma, are excluded unless ALL of the following criteria for describing the endometrial carcinoma are met: Stage = Ib, no more than superficial myometrial invasion, no lymphovascular invasion, not poorly differentiated (i.e., not Grade 3 or papillary serous or clear cell).
- •- Diagnosis of any second malignancy within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix uteri.
- •- Prior treatment with a humanized monoclonal antibody anticancer therapeutic.
- •- Prior treatment with investigational treatment targeted to IGF axis including, but not limited to, CP 751,871, IM-A12, RO4858696.
- •- Previous exposure to AMG 479.
- •- Anticipation of a need for a major surgical procedure or radiation therapy during the study.
- •- History of hypersensitivity to recombinant proteins.
- •- Treatment with radiotherapy, surgery, or an investigational agent within 4 weeks of randomization.
- •- Any of the following within 6 months prior to study enrollment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, NYHA class III or IV congestive heart failure, cerebrovascular accident or transient ischemic attack, grade = 2 peripheral neuropathy, pulmonary embolism, deep vein thrombosis, or other thromboembolic event.
- •- History of brain metastases, spinal cord compression, or carcinomatous meningitis.
- •- Patient of child-bearing potential is pregnant (eg, positive human chorionic gonadotropin test) or is breast feeding.
- •- Patient of child-bearing potential is not willing to use adequate contraceptive precautions.
- •- Known active infection, or on antiretroviral therapy for HIV disease.
- •- Known positive test for chronic hepatitis B or C infection.
- •- Any other underlying physical or mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study.
- •- Refusal or inability to give informed consent to participate in the study.
- •- Other severe acute or chronic medical or psychiatric condition, or significant laboratory abnormality requiring further investigation that may cause undue risk for the patient’s safety, inhibit protocol participation, or interfere with interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of RO7123520 as Adjunct Treatment in Patients With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to TNF-a InhibitorsMedDRA version: 20.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2016-002126-36-ESF. Hoffmann-La Roche Ltd204
进行中（未招募）
1 期
Efficacy and safety study evaluating a new sublingual treatment in HDM allergic rhinitisHouse dust mite allergic rhinitisMedDRA version: 18.0Level: LLTClassification code 10001725Term: Allergic rhinitis due to other allergenSystem Organ Class: 100000004855EUCTR2014-004223-46-ESStallergenes S.A.990
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, multicenter study of the efficacy and safety of Ritalin® LA in adult patients with childhood-onset ADHDAdult patients with childhood-onset Attention Deficit Hyperactivity DisorderMedDRA version: 12.1Level: LLTClassification code 10003735Term: Attention deficit-hyperactivity disorderMedDRA version: 12.1Level: LLTClassification code 10003736Term: Attention deficit/hyperactivity disorderMedDRA version: 12.1Level: LLTClassification code 10003737Term: Attention deficit/hyperactivity disorder NOSMedDRA version: 12.1Level: PTClassification code 10003736Term: Attention deficit/hyperactivity disorderEUCTR2010-021533-31-DKovartis Pharma Services AG700
进行中（未招募）
1 期
Safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathyDiabetic nephropathyMedDRA version: 16.1 Level: PT Classification code 10061835 Term: Diabetic nephropathy System Organ Class: 10038359 - Renal and urinary disordersEUCTR2012-004179-38-NLBayer HealthCare AG823
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapyDiffuse Large B-Cell LymphomaMedDRA version: 19.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-000498-40-DEovartis Pharma Services AG487